Publication:
Taurolidine as adjuvant treatment of relapsing peritonitis in peritoneal dialysis patients.

dc.contributor.authorKlimek, Kamila
dc.contributor.authorAresté Fosalba, Nuria
dc.contributor.authorRamírez López, Miguel Ángel
dc.contributor.authorGómez Castilla, Antonia Concepción
dc.contributor.authorSalgueira Lazo, Mercedes
dc.date.accessioned2023-01-25T13:35:13Z
dc.date.available2023-01-25T13:35:13Z
dc.date.issued2019-06-15
dc.description.abstractRelapsing peritonitis in peritoneal dialysis patients is one of the complications that jeopardizes the continuity of the technique. It is often associated with the formation of biofilm in the lumen of the catheter. To date, its removal remains the only recommended attitude. Due to its antimicrobial and antifungal properties, taurolidine has been previously used for the sealing of central line catheters and hemodialysis. Despite the good results obtained, there is no evidence available regarding its utility in peritoneal dialysis. This case report describes the use of taurolidine (TauroLock™HEP500) in 5 patients with relapsing peritonitis after antibiotic treatment completion. Mean follow-up for the detection of recurrences was 13.4 months. In 4 patients with infections caused by Staphylococcus epidermidis, eradication was achieved. In the remaining case, caused by Staphylococcus aureus, the taurolidine seal was ineffective and the removal of the catheter was required.
dc.identifier.doi10.1016/j.nefro.2019.03.014
dc.identifier.essn2013-2514
dc.identifier.pmid31208832
dc.identifier.unpaywallURLhttps://doi.org/10.1016/j.nefro.2019.03.014
dc.identifier.urihttp://hdl.handle.net/10668/14134
dc.issue.number2
dc.journal.titleNefrologia
dc.journal.titleabbreviationNefrologia (Engl Ed)
dc.language.isoen
dc.language.isoes
dc.organizationHospital Universitario Virgen del Rocío
dc.organizationHospital Universitario Virgen Macarena
dc.page.number197-201
dc.pubmedtypeCase Reports
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectBiofilm
dc.subjectDiálisis peritoneal
dc.subjectPeritoneal dialysis
dc.subjectPeritonitis
dc.subjectTaurolidina
dc.subjectTaurolidine
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshAnti-Bacterial Agents
dc.subject.meshAnti-Infective Agents, Local
dc.subject.meshCatheter-Related Infections
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshPeritoneal Dialysis
dc.subject.meshPeritonitis
dc.subject.meshRecurrence
dc.subject.meshStaphylococcal Infections
dc.subject.meshStaphylococcus aureus
dc.subject.meshStaphylococcus epidermidis
dc.subject.meshTaurine
dc.subject.meshThiadiazines
dc.subject.meshVancomycin
dc.titleTaurolidine as adjuvant treatment of relapsing peritonitis in peritoneal dialysis patients.
dc.title.alternativeTaurolidina como tratamiento adyuvante en casos de peritonitis recidivante en pacientes en diálisis peritoneal.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number40
dspace.entity.typePublication

Files